Voluntary nationwide recall: Atorvastatin (Alkem – October)

Nov. 2025Pharmacy Updates

Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.

This drug is being recalled because the products do not dissolve at the expected rate in the body. This may cause the product to be less effective.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Atorvastatin, you should stop using the product and return it to the place of purchase or discard it.

As of Oct. 10, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.


Recent Announcements

CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.
Aug. 2026Education/Webinars

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Aug. 2026Education/Webinars

Watch for a chance to rate your experience with UPMC Health Plan

Watch for a chance to rate your experience with UPMC Health Plan. You may be randomly selected to participate in a 2026 Press Ganey provider satisfaction survey that will begin this month.
Aug. 2026Important Notices